DENOVA Sciences PTE. Limited, Co-Founder & Director
Specialised in humanised 3D Asian skin Organoid that can serve as flexible and powerful platform that caters to a wide range of testing methods. Cofounds Denova Sciences in late 2012 where he assumes the roles of Chief Scientific Officer overseeing the technology and innovation operation and development. Developed in-vitro Asian Skin model using a proprietary Organoid Technology for a wide variety of testing application and driving DeNova in achieving GLP standards in the coming years.
Established as a key technical expertise in skin testing area in Singapore and was called upon to assume the role of Vice President & Scientific Chairperson in SCSS (Singapore). Not only he is passionate about his skin research areas, he also hopes to bring the science research communities and personal care industrial players closer to better enhance innovation and technologies exchange.
In 2018 Denova also comply to the OECD 428 permeation guideline to study skin penetration and retention of actives ingredients and subsequently in 2019, they also developed the testing methodology that comply to OECD 431 and 439 skin irritation and corrosion. In 2020, he also created an UVA-induced aged skin coculture that can better study the ant-aging potential of an anti-aging product. Till present, he has secured CRO partners in Singapore, France, Thailand, Indonesia and Malaysia for human clinical studies and certified anti-microbiome testing (including virucidal, bactericidal, HFMD and Corona 229E etc).
He was also involved in a consultancy project with a MNC from Japan in setting up and fully equipped their biological lab in Singapore. In 2020, he also consulted a Singapore firm Materra Solution in partner with Beyonics in setting up an SOP for the manufacturing of PBS filled tube meant for covid swab kit. He was detailed and trained the management and production team of Beyonics to complied to the requirement of the aseptic production of the PBS filled tube.
In recent time, he also has ventured into the 3D Bioprinting field to start numerous collaborations in bioprinting of Asian Skin organoids to increase reproducibility and up-scaling potential. Currently, he is working on to develop intestine and lungs models to create testing for all types of consumer products. He visions DeNova in creating an organoids systemic platform that can better evaluate and understand the product in the most ethical way to safeguard the consumer health and enhance quality.
In Recent times, Denova Sciences has partnered with China and Indonesia CRO to extend their services into regulatory affair, product registration and human consumer study.
Research Project Officer. 2006 - 2014
Laboratory of Professor Tan Nguan Soon, Andrew, School of Biological Sciences, Nanyang Technological University, Singapore.
Collaboration projects involving National Skin Centre, and various MNC. Research project involved the investigation of the interplay of TGF-β signalling in TGF-β, Smad3 and TAK1 knockdown fibroblasts. Involvement in numerous Patent creations and paper publishing
•专注于亚洲人种三维类人皮肤类器官的研发，该平台支持广泛的检测应用。
•负责公司技术与创新运营，自主开发类器官技术，推动公司向GLP标准迈进。
•是新加坡皮肤测试领域的关键技术专家，曾担任新加坡化妆品科学家学会（SCSS）副会长与科学主席。
•先后建立OECD 428（皮肤渗透）、431和439（皮肤刺激与腐蚀）标准的测试方法。
•创造UVA诱导老化的皮肤共培养模型，用于抗衰产品测试。
•已与新加坡、法国、泰国、印尼及马来西亚的CRO建立临床合作，覆盖抗微生物、抗病毒（如HFMD、冠状病毒229E）测试。
•也曾协助日本跨国企业在新加坡设立生物实验室，及新加坡Materra与Beyonics合作，为新冠PBS试剂管设立GMP SOP并培训管理与生产团队。
•近期进入3D生物打印领域，发展亚洲皮肤类器官的规模化生产；正在开发肠道与肺部模型。
•公司正构建类器官系统平台，实现伦理且高质量的消费品安全评估。
•目前Denova已与中国、印尼CRO合作，扩展至注册事务与消费者研究服务。
研究项目专员（2006 – 2014）
新加坡南洋理工大学生物科学学院
•与国家皮肤中心及多家跨国企业合作，研究TGF-β信号通路在皮肤纤维母细胞中的作用，参与多个专利和论文发表。